Microsite Matches Oncology Sponsors with Canadian Investigators
Scimega Research, an oncology-focused CRO, has launched its new Reverse Feasibility Resource Center
Scimega Research, (www.scimega.com) an oncology-focused CRO, has launched its new Reverse Feasibility Resource Center, that is aimed at matching U.S. oncology sponsors in need of Canadian investigators and their patients.
This microsite will be updated regularly to highlight Canada’s expertise in both early and late phase oncology trials. It currently features important information such as the number of oncology sites, key investigators, and the size of the catchment areas for each of the ten Canadian provinces. Sponsors can sign up to receive free quarterly updates on the types of trials Scimega’s Reverse Feasibility Champions are looking to participate in. This Oncology Trial Needs Report for Canada will highlight the number of sites actively looking for a trial, including lines of treatment, tumor types and targets.
Read the full release here.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
